<!DOCTYPE html>

<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Successful outcome of neoadjuvant PD-1 blockade, VEGFR-2 inhibitor plus chemotherapy for potentially unresectable esophagogastric junctional squamous cell carcinoma: a case report.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Successful outcome of neoadjuvant PD-1 blockade, VEGFR-2 inhibitor plus chemotherapy for potentially unresectable esophagogastric junctional squamous cell carcinoma: a case report." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b1b/9552059/0bba04c765a2/tcr-11-09-3329-f3.jpg"/> </div> <div class="text-side"> <h1>Successful outcome of neoadjuvant PD-1 blockade, VEGFR-2 inhibitor plus chemotherapy for potentially unresectable esophagogastric junctional squamous cell carcinoma: a case report.</h1> <p>IHC staining of the specimens. (A) Positivity of IHC staining in the biopsy specimens for PD-L1 with PD-L1 CPS of 30 (×100). (B) Positivity of IHC staining for PD-L1 (×200). (C) H&amp;E staining in the resected specimens exhibited SCC (×100). (D) H&amp;E staining (×200). (E) Positivity of IHC staining for MLH1 (×200). (F) Positivity of IHC staining for MSH2 (×200). (G) Positivity of IHC staining for MSH6 (×200). (H) Positivity of IHC staining for PMS2 (×200). (I) The Ki-67 was 60% (×200). IHC, immunohistochemical; PD-L1, programmed death-ligand 1; CPS, combined positive score; H&amp;E, hematoxylin and eosin; SCC, squamous cell carcinoma; MLH1, mutL protein homolog 1; MSH2, mutS homolog 2; MSH6, mutS homolog 6; PMS2, postmeiotic segregation increased 2.</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/36237240/" target="_blank">36237240</a></p><p>Type: Premalignant/Malignant, Category: Keratinocytic</p>
</div> </div></div></body></html>